Log in

CytomX Therapeutics Price Target, Predictions & Analyst Ratings

-0.11 (-1.62 %)
(As of 09/28/2020 12:00 AM ET)
Today's Range
Now: $6.69
50-Day Range
MA: $6.98
52-Week Range
Now: $6.69
Volume188,722 shs
Average Volume529,905 shs
Market Capitalization$309.02 million
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

CytomX Therapeutics (NASDAQ:CTMX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for CytomX Therapeutics in the last 12 months. Their average twelve-month price target is $11.94, predicting that the stock has a possible upside of 78.54%. The high price target for CTMX is $16.00 and the low price target for CTMX is $7.00. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
CTMX Consensus Rating: BuyBuyBuyBuy
CTMX Consensus Rating Score: 2.632.752.782.88
CTMX Analyst Ratings: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
CTMX Consensus Price Target: $11.94$12.38$12.38$14.14
CTMX Price Target Upside: 78.54% upside63.91% upside39.67% upside186.87% upside

CytomX Therapeutics (NASDAQ:CTMX) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CytomX Therapeutics (NASDAQ:CTMX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2020GuggenheimDowngradeBuy ➝ NeutralLow
9/15/2020CitigroupLower Price Target$11.00 ➝ $8.50Low
8/7/2020HC WainwrightReiterated RatingBuy$12.00Medium
6/1/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.00 ➝ $10.00High
5/29/2020MizuhoReiterated RatingBuy$16.00Low
5/17/2020NomuraReiterated RatingBuy$15.00High
3/24/2020WedbushUpgradeNeutral ➝ OutperformLow
3/4/2020BarclaysInitiated CoverageEqual Weight$7.00Low
2/28/2020Nomura SecuritiesLower Price TargetBuy$22.00 ➝ $15.00High
8/7/2019CowenReiterated RatingBuyHigh
6/3/2019Cantor FitzgeraldReiterated RatingOverweight$21.00 ➝ $23.00High
2/28/2019SunTrust BanksLower Price TargetBuy$18.00Low
12/13/2018Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
12/2/2018Piper Jaffray CompaniesInitiated CoverageOverweight$13.24High
3/8/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$34.00 ➝ $40.00High
10/4/2017OppenheimerReiterated RatingHoldHigh
(Data available from 9/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.